News / Health

Race On to Develop New Antibiotics

Carbapenem-resistant Klebsiella pneumoniae bacteria
Carbapenem-resistant Klebsiella pneumoniae bacteria

Multimedia

Vidushi Sinha

Drug companies are struggling to develop new and more effective antibiotics to combat the growing worldwide threat from drug-resistant germs.  In this second of her 2-part report on "Battling Superbugs," we examine the looming public health danger, and the challenges drug companies face in bringing new antibiotics to market.

Medical experts watching the rising tide of drug-resistant bacteria have begun sounding the alarms.  They say life-threatening infections could jeopardize surgeries, cancer treatment, organ transplants, and many other specialized medical procedures.

And some warn that if new anti-microbial drugs are not developed within the next few years, billions of people will be left nearly defenseless against some lethal bacterial infections.

Such concerns have prompted the Infectious Disease Society of America (IDSA) to call for the development of 10 new antibiotic drugs by the year 2020, an initiative the group calls "10 by 20."

“The 10 by 20 initiative is IDSA’s challenge to the global community to come together to bring the right group of people together. People in government, industry, academia, policy makers to figure out the right combination of incentives that both will motivate companies who want to develop new antibiotics and also to find new ways to manage these products over time," said Robert Guidos, Vice President of IDSA.

Experts say that the hour of reckoning has arrived, and that if efforts to combat the problem are not launched now, dangerous diseases eradicated long ago could make a comeback.

Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, shared that concern recently with Capitol Hill lawmakers. "If we don't improve our response to the public health problem of antibiotic resistance, we may enter a post- antibiotic world in which we will have few or no clinical interventions for some infections," he said.

Recent studies have shown that there are very few new antibiotics in the development pipeline that would work against lethal infections born out of bacterial resistance such as Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, or carbapenem-resistant Klebsiella pneumoniae, or CRKP for short.

About 2 million MRSA infections have been reported in U.S. hospitals each year since 2002.

Barry Eisenstein is Vice President of Cubist, an American drug company with a new anti-MRSA drug in development, as well as many others.

He says neither the federal regulatory environment nor the pharmaceutical market are favorable for companies trying to develop antibiotics. “The expense and difficulty of doing these...trials for the most important diseases have become very hard and very difficult to the point that many of the big companies have actually gotten out of the field of antibiotic development because they don’t feel that it’s worth the investment," he said.

Some drug company executives contend that financial returns on investments made in a new antibiotic are significantly lower than for other new drugs reaching the market.

“Think about the cholesterol-lowering drug - it’s not uncommon for many of the statins to be bringing in $5 - 10 or more billions per year. For an antibiotic to sell at a half a billion is considered a blockbuster, almost unheard of," he said.

Eisenstein says the push to make "a perfect drug" that is both safe and effective beyond a shadow of doubt has considerably slowed the pace of new antibiotics reaching the market.

To get companies back in the antibiotics game, Eisenstein says two things have to be done.

“The regulatory risk - to decrease the great hurdles to get approval and increase the likelihood of being able to get a drug approved in a shorter period of time, at a higher proportion of probability. And then on the economic side, to enable the companies to have greater incentives to overcome what we call market failure," he said.

Drug companies note that the newest antibiotics, typically, are likely to be prescribed more carefully and used more sparingly - meaning slower sales and smaller profits for the companies that develop them.

Neverthless, public health experts say one new antibiotic has already been approved for use in the United States, and they are hopeful that the ambitious goal  of developing nine more by 2020 can be achieved.

You May Like

Mali's Female Basketball Players Rebound After Islamist Occupation

Islamist extremists ruled northern Mali for most of 2012, imposing strict Sharia law, and now some 18 months later, the region is slowly getting back on its feet More

Video Vietnamese Staging Chinese Product Boycott After Oil Rig Spat

Many Chinese-made products go unsold, for now, with numerous Vietnamese consumers still angry over recent dispute More

Koreas Mark 61st Anniversary of War Armistice

Muted observances on both sides of heavily-armed Demilitarized Zone that separates two decades-long enemies More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Students in Business for Themselvesi
X
Mike O'Sullivan
July 26, 2014 11:04 AM
They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Students in Business for Themselves

They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Astronauts Train in Underwater Lab

In the world’s only underwater laboratory, four U.S. astronauts train for a planned visit to an asteroid. The lab - called Aquarius- is located five kilometers off Key Largo, in southern Florida. Living in close quarters and making excursions only into the surrounding ocean, they try to simulate the daily routine of a crew that will someday travel to collect samples of a rock orbiting far away from earth. VOA’s George Putic has more.
Video

Video Not Even Monks Spared From Thailand’s Junta-Backed Morality Push

With Thailand’s military government firmly in control after May’s bloodless coup, authorities are carrying out plans they say are aimed at restoring discipline, morality and patriotism to all Thais. The measures include a crackdown on illegal gambling, education reforms to promote students’ moral development, and a new 24-hour phone hotline for citizens to report misbehaving monks. Steve Sandford reports from Bangkok.
Video

Video Virtual Program Teaches Farming Skills

In a fast-changing world beset by unpredictable climate conditions, farmers cannot afford to ignore new technology. Researchers in Australia are developing an online virtual world program to share information about climate change and more sustainable farming techniques for sugar cane growers. As VOA's Zlatica Hoke reports, the idea is to create a wider support network for farmers.
Video

Video Airline Expert: Missile will Show Signature on Debris

The debris field from Malaysia Airlines Flight 17 is spread over a 21-kilometer radius in eastern Ukraine. It is expected to take investigators months to sort through the airplane pieces to learn about the missile that brought down the jetliner and who fired it. VOAs Carolyn Presutti explains how this work will be done.
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.

AppleAndroid